Poustis-Delpont C, Thaon S, Auberger P, Gerardi-Laffin C, Sudaka P, Rossi B
Laboratoire de Biochimie, Faculté de Médecine, Nice, France.
J Biol Chem. 1994 May 20;269(20):14666-71.
Guanidinobenzoatases are cell surface enzymes present in cells capable of migration or remodeling. The guanidinobenzoatase purified to homogeneity from human renal carcinoma did not display gelatinase activity under the 55-kDa form (Poustis-Delpont, C., Descomps, R., Auberger, P., Delque-Bayer, P., Sudaka, P., and Rossi, B. (1992) Cancer Res. 52, 3622-3628). We bring new insights into the structure-activity relationships of this enzyme using sodium dodecyl sulfate-polyacrylamide gel electrophoresis, [3H]diisopropyl fluorophosphate labeling, gelatin zymography, and immunodetection using a polyclonal antibody raised against the 55-kDa entity. Upon aggregation into a 220-kDa form, the enzyme exhibited [3H]diisopropyl fluorophosphate labeling and diisopropyl fluorophosphate-inhibitable gelatinase activity whereas its capability to cleave p-nitrophenyl p'-guanidinobenzoate as a substrate was abolished. Thus, the guanidinobenzoatase property appears as a feature of a 55-kDa inactive form of a serine proteinase subunit. After boiling in the presence of sodium dodecyl sulfate (3% w/v), the 220-kDa entity subjected to SDS-polyacrylamide gel electrophoresis could be dissociated into a 55-kDa protein as shown by silver staining. The resulting 55-kDa band remained [3H]diisopropyl fluorophosphate-labeled and reacted with anti-55-kDa guanidinobenzoatase antibodies, strongly suggesting that the 220-kDa proteinase was a noncovalently associated tetramer. Interestingly, Triton X-100 extracts of renal carcinoma plasma membranes exhibited a 220-kDa serine proteinase activity, as expressed in gelatin zymography, which was barely detectable in the non-tumoral counterpart. It is noteworthy that an anti-55-kDa guanidinobenzoatase reactive 220-kDa species was also observed in renal carcinoma plasma membranes extracts as assessed by Western blot, whereas it was hardly visible in the non-tumoral counterpart. No signal was immunodetected at M(r) 55,000 in renal carcinoma and kidney cortex membranes in Western blot experiments. Taken together, our data support the idea that the enzyme is expressed under its tetrameric form in the membrane. The purified enzyme is able to exhibit a serine proteinase activity when it recovers its native tetrameric form. This high molecular weight tetrameric proteinase SP 220 K appears as a new member of the cell surface serine protease family.
胍基苯甲酸酶是存在于能够迁移或重塑的细胞中的细胞表面酶。从人肾癌中纯化至同质的胍基苯甲酸酶在55 kDa形式下未显示明胶酶活性(普斯蒂斯 - 德尔蓬特,C.,德孔普斯,R.,奥伯格,P.,德尔克 - 拜尔,P.,苏达卡,P.,和罗西,B.(1992年)癌症研究。52,3622 - 3628)。我们使用十二烷基硫酸钠 - 聚丙烯酰胺凝胶电泳、[3H]二异丙基氟磷酸标记、明胶酶谱分析以及使用针对55 kDa实体产生的多克隆抗体进行免疫检测,对这种酶的构效关系有了新的认识。聚合成220 kDa形式后,该酶表现出[3H]二异丙基氟磷酸标记和二异丙基氟磷酸可抑制的明胶酶活性,而其切割对硝基苯基对 - 胍基苯甲酸酯作为底物的能力丧失。因此,胍基苯甲酸酶特性似乎是丝氨酸蛋白酶亚基55 kDa无活性形式的一个特征。在十二烷基硫酸钠(3% w/v)存在下煮沸后,经十二烷基硫酸钠 - 聚丙烯酰胺凝胶电泳的220 kDa实体可解离成55 kDa蛋白质,银染显示如此。所得的55 kDa条带仍保持[3H]二异丙基氟磷酸标记,并与抗55 kDa胍基苯甲酸酶抗体反应,强烈表明220 kDa蛋白酶是一种非共价结合的四聚体。有趣的是,肾癌质膜的Triton X - 100提取物表现出220 kDa丝氨酸蛋白酶活性,如明胶酶谱分析所示,在非肿瘤对应物中几乎检测不到。值得注意的是,通过蛋白质印迹评估,在肾癌质膜提取物中也观察到一种抗55 kDa胍基苯甲酸酶反应性的220 kDa物质,而在非肿瘤对应物中几乎不可见。在蛋白质印迹实验中,肾癌和肾皮质膜在55,000相对分子质量处未检测到免疫信号。综上所述,我们的数据支持该酶在膜中以其四聚体形式表达的观点。纯化的酶在恢复其天然四聚体形式时能够表现出丝氨酸蛋白酶活性。这种高分子量四聚体蛋白酶SP 220 K似乎是细胞表面丝氨酸蛋白酶家族的一个新成员。